DataMEDS AI (MEDS) Stock Soars 87% Following Helomics Cancer Lab Acquisition
DataMEDS AI (MEDS) stock soared 87% after finalizing its $1.5M Helomics acquisition, gaining access to the $40B U.S. cancer diagnostics market.
The post DataMEDS AI (MEDS) Stock Soars 87% Following Helomics Cancer Lab Acquisition appeared first on Blockonomi.
Source: Source: Blockonomi